eprintid: 10061497
rev_number: 29
eprint_status: archive
userid: 608
dir: disk0/10/06/14/97
datestamp: 2018-11-15 13:33:41
lastmod: 2021-09-20 00:25:33
status_changed: 2019-02-20 16:30:35
type: article
metadata_visibility: show
creators_name: Pose, E
creators_name: Trebicka, J
creators_name: Mookerjee, RP
creators_name: Angeli, P
creators_name: Ginès, P
title: Statins: Old drugs as new therapy for liver diseases
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G91
keywords: Chronic liver diseases, Decompensation, Pleiotropic effects, Portal hypertension, Statins
note: This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
abstract: In addition to lowering cholesterol levels, statins have pleiotropic effects, particularly anti-inflammatory, antiangiogenic, and antifibrotic, that may be beneficial in some chronic inflammatory conditions. Statins have only recently been investigated as a potential treatment option in chronic liver diseases because of concerns related to their safety in patients with impaired liver function. A number of experimental studies in animal models of liver diseases have shown that statins decrease hepatic inflammation, fibrogenesis and portal pressure. In addition, retrospective cohort studies in large populations of patients with cirrhosis and pre-cirrhotic conditions have shown that treatment with statins, with the purpose of decreasing high cholesterol levels, was associated with a reduced risk of disease progression, hepatic decompensation, hepatocellular carcinoma development, and death. These beneficial effects persisted after adjustment for disease severity and other potential confounders. Finally, a few randomised controlled trials have shown that treatment with simvastatin decreases portal pressure (two studies) and mortality (one study). Statin treatment was generally well tolerated but a few patients developed severe side effects, particularly rhabdomyolysis. Despite these promising beneficial effects, further randomised controlled trials in large series of patients with hard clinical endpoints should be performed before statins can be recommended for use in clinical practice.
date: 2019-01
date_type: published
official_url: https://doi.org/10.1016/j.jhep.2018.07.019
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1575947
doi: 10.1016/j.jhep.2018.07.019
pii: S0168-8278(18)32275-X
lyricists_name: Mookerjee, Rajeshwar
lyricists_id: RPMOO69
actors_name: Cuccu, Clara
actors_id: CCCUC40
actors_role: owner
full_text_status: public
publication: Journal of Hepatology
volume: 70
number: 1
pagerange: 194-202
event_location: Netherlands
issn: 1600-0641
citation:        Pose, E;    Trebicka, J;    Mookerjee, RP;    Angeli, P;    Ginès, P;      (2019)    Statins: Old drugs as new therapy for liver diseases.                   Journal of Hepatology , 70  (1)   pp. 194-202.    10.1016/j.jhep.2018.07.019 <https://doi.org/10.1016/j.jhep.2018.07.019>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10061497/8/Mookerjee%20VoR1-s2.0-S016882781832275X-main.pdf